We have performed an in-vivo study with the new formulation in an established hair growth model in mice. After application of the highest dose five times a week we observed a clear increase in hair growth. The positive results from the in vivo study are very important since we received concrete evidence that the treatment with the formulation really works, with a demonstrated stimulation of hair growth. In the study we also compared FOL-005 with an established treatment, Minoxidil 5% administrated twice daily, and the results for both treatments were during the main part of the study equal.
Follicum filed a patent application for the new topical formulation during the spring. The formulation is intended for application on the scalp and has demonstrated good hair stimulating effect in an animal model. If the patent application is approved, the protection for FOL-005 will be extended with 8 years. The next step for the formulation is to be tested in the clinical phase II trial on alopecia patients, which is planned to start at the end of 2019.
In the beginning of 2019, Follicum employed two post-doctoral scientists to establish an in-house laboratory for in vitro studies of Follicum’s peptides and the effects on diabetes and its complications.
LUDC (Lund University Diabetes Centre) has been granted a post-doc to study the Mode of Action (MoA) of our diabetes peptides. Dr Chrysostomi Gialeli is the latest addition of resources to Follicum on a post-doc employment to speed up the research with the aim to strengthening the potential of Follicum’s peptides for future diabetes treatment.